Randomized phase II study of axitinib versus standard of care in patients with recurrent glioblastoma.
Bart Neyns
Research Funding - Pfizer
Johnny Duerinck
Other Remuneration - Pfizer
Stephanie Du Four
No relevant relationships to disclose
Frank Bouttens
No relevant relationships to disclose
Vincent Verschaeve
No relevant relationships to disclose
Hendrik Everaert
No relevant relationships to disclose
An Van Binst
No relevant relationships to disclose